Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

01 Mar 2011
Director/PDMR Shareholding

March 1, 2011 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that on February 28, 2011 the following Persons Discharging Managerial Responsibility ("PDMRs") were granted awards under the Shire Portfolio Share Plan (the "Plan").

Awards of Stock Appreciation Rights ("SARs") under Part A of the Plan

Name of PDMRType of SecurityNo of Ordinary Shares or ADSsExercise price
Angus Russell (Chief Executive Officer)*ADSs63,015$83.79
Graham Hetherington (Chief Financial Officer)*Ordinary Shares82,873£17.23
Tatjana MayOrdinary Shares28,379£17.23
Michael ColaADSs13,552$83.79
Sylvie GregoireADSs13,552$83.79
Barbara DeptulaADSs7,896$83.79
*Vesting of awards granted to Executive Directors is subject to performance targets

SARs will normally vest after three years, subject to any performance targets having been satisfied. Vested SARs will be capable of exercise for a period of four years. No consideration was paid for the grant of the SARs.

Performance Share Awards ("PSA Awards") under Part B of the Plan

Name of PDMRType of SecurityNo of Ordinary Shares or ADSsMarket Value
Angus Russell (Chief Executive Officer)*ADSs47,262$83.79
Graham Hetherington (Chief Financial Officer)*Ordinary Shares60,769£17.23
Tatjana MayOrdinary Shares20,433£17.23
Michael ColaADSs9,938$83.79
Sylvie GregoireADSs9,938$83.79
Barbara DeptulaADSs5,685$83.79
*Vesting of awards granted to Executive Directors is subject to performance targets

The PSA Awards will normally vest after three years, subject to any performance targets having been satisfied. Once vested, sufficient ordinary shares or ADSs will be transferred or allotted to the participant within 30 days. No consideration was paid for the grant of the PSA Awards.

This notification is made to satisfy the Company's obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie
Deputy Company Secretary

 

For further information please contact:

Investor Relations  
Eric Rojaserojas@shire.com+1 781 482 0999

 

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

01 Mar 2011 Director/PDMR Shareholding (16KB PDF)

« Back to Shire news

Did you know...

You can sign up to receive email and SMS alerts so that you can keep up to speed with our latest news.

Email and SMS alerts

Did you know...

We donated over $35,000 in
outdated laboratory
equipment
to local
schools?